1.685
price up icon3.11%   0.075
 
loading
Precedente Chiudi:
$1.61
Aprire:
$1.61
Volume 24 ore:
8,743
Relative Volume:
0.06
Capitalizzazione di mercato:
$39.04M
Reddito:
$48.20M
Utile/perdita netta:
$-35.05M
Rapporto P/E:
-1.0751
EPS:
-1.5673
Flusso di cassa netto:
$-13.02M
1 W Prestazione:
+6.75%
1M Prestazione:
-11.23%
6M Prestazione:
-23.85%
1 anno Prestazione:
-50.89%
Intervallo 1D:
Value
$1.5345
$1.72
Intervallo di 1 settimana:
Value
$1.47
$1.7699
Portata 52W:
Value
$1.06
$5.22

Celularity Inc Stock (CELU) Company Profile

Name
Nome
Celularity Inc
Name
Telefono
(908) 768-2170
Name
Indirizzo
170 PARK AVE, FLORHAM PARK
Name
Dipendente
120
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
CELU's Discussions on Twitter

Confronta CELU con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CELU
Celularity Inc
1.6959 39.04M 48.20M -35.05M -13.02M -1.5673
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.33 124.91B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
594.23 60.05B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
603.50 35.88B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.79 29.83B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.20 24.58B 3.81B -644.79M -669.77M -6.24

Celularity Inc Stock (CELU) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-01-30 Downgrade Morgan Stanley Equal-Weight → Underweight
2022-12-22 Downgrade Oppenheimer Outperform → Perform
2022-06-22 Iniziato H.C. Wainwright Buy
2022-04-06 Downgrade Truist Buy → Hold
2022-01-28 Iniziato Oppenheimer Outperform
2021-11-24 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Celularity Inc Borsa (CELU) Ultime notizie

pulisher
Apr 23, 2025

Celularity faces Nasdaq delisting over late filing By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

Celularity faces Nasdaq delisting over late filing - Investing.com

Apr 23, 2025
pulisher
Apr 14, 2025

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

CMS Extends Medicare Coverage for Wound Care Products: Major Win for Skin Substitute Market - Stock Titan

Apr 14, 2025
pulisher
Apr 07, 2025

Revolutionary NK Cell Therapy Shows Promise in Cancer Treatment: New Research Reveals - Stock Titan

Apr 07, 2025
pulisher
Apr 04, 2025

Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology - The Globe and Mail

Apr 04, 2025
pulisher
Mar 31, 2025

Celularity Delays Yearly Report Filing Amid Financial Challenges - TipRanks

Mar 31, 2025
pulisher
Mar 22, 2025

Celularity extends debt maturity, issues stock to investor By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 21, 2025

Celularity enters into standby equity purchase agreement with Ya Ii Pn -March 21, 2025 at 04:39 pm EDT - MarketScreener

Mar 21, 2025
pulisher
Mar 21, 2025

Celularity enters into standby equity purchase agreement with Ya Ii Pn - TradingView

Mar 21, 2025
pulisher
Mar 17, 2025

Robust Growth in Regenerative Placental Cell Therapy Market - openPR.com

Mar 17, 2025
pulisher
Feb 28, 2025

Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 26, 2025

Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio to Support Cell Therapy Manufacturing - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Celularity Secures Crucial FDA Pathway for Wound Care ProductsCan They Capture Share of $810M Market? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

Celularity inks manufacturing deal with BlueSphere Bio By Investing.com - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

Celularity inks manufacturing deal with BlueSphere Bio - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential? - StockTitan

Feb 24, 2025
pulisher
Feb 21, 2025

Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry - Simply Wall St

Feb 21, 2025
pulisher
Feb 20, 2025

Celularity Inc. Extends Loan Agreements with Resorts World Inc and C.V. Starr & Co. - Defense World

Feb 20, 2025
pulisher
Feb 13, 2025

SEC Form FWP filed by Celularity Inc. - Quantisnow

Feb 13, 2025
pulisher
Feb 10, 2025

Celularity Inc (CELU) Stock: Analyzing the Market Value - The News Heater

Feb 10, 2025
pulisher
Feb 06, 2025

Celularity Inc (CELU) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Feb 06, 2025
pulisher
Feb 06, 2025

Placental Stem Cell Therapy Solution Market Size And Booming - openPR

Feb 06, 2025
pulisher
Feb 01, 2025

Celularity files to sell 6.52M shares of Class A common stock, warrants - MSN

Feb 01, 2025
pulisher
Jan 27, 2025

Celularity cancels material agreement with investor - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Celularity amends warrant terms, secures $2.46 million funding By Investing.com - Investing.com Canada

Jan 27, 2025
pulisher
Jan 27, 2025

Celularity amends warrant terms, secures $2.46 million funding - Investing.com India

Jan 27, 2025
pulisher
Jan 27, 2025

MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs - The Manila Times

Jan 27, 2025
pulisher
Jan 25, 2025

Celularity cancels material agreement with investor By Investing.com - Investing.com

Jan 25, 2025
pulisher
Jan 24, 2025

Celularity Faces Challenges as Agreement Expires - TipRanks

Jan 24, 2025
pulisher
Jan 21, 2025

Celularity Inc. (NASDAQ:CELU) Short Interest Up 7.1% in December - Defense World

Jan 21, 2025
pulisher
Jan 11, 2025

Celularity (NASDAQ:CELU) Shares Down 0.5% – Here’s What Happened - Defense World

Jan 11, 2025
pulisher
Jan 03, 2025

Amniotic Products Global Industry Report 2025: Growth in Regenerative Medicine Propels the Use of Amniotic Products in Tissue Repair and Healing - GlobeNewswire Inc.

Jan 03, 2025
pulisher
Dec 22, 2024

**Celularity Inc. Holds Annual Meeting and Reports Voting Results** - Defense World

Dec 22, 2024
pulisher
Dec 10, 2024

CELUCelularity Inc. Latest Stock News & Market Updates - StockTitan

Dec 10, 2024
pulisher
Dec 10, 2024

Celularity announces resolution of Nasdaq listing compliance matter - Nasdaq

Dec 10, 2024
pulisher
Dec 10, 2024

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

Celularity Restores Nasdaq Compliance After Major Financial Reporting Overhaul - StockTitan

Dec 10, 2024
pulisher
Dec 07, 2024

Celularity reports Q3 EPS (73c) vs. ($4.98) last year - MSN

Dec 07, 2024
pulisher
Dec 06, 2024

Celularity Gets Back On Track With Quarterly Submissions; Q3 Revenue Jump 145% - Nasdaq

Dec 06, 2024
pulisher
Dec 06, 2024

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 - The Manila Times

Dec 06, 2024

Celularity Inc Azioni (CELU) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Celularity Inc Azioni (CELU) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Hariri Robert J
Chief Executive Officer
Apr 13 '25
Option Exercise
0.00
3,281
0
21,482
Haines John R
Senior Exec Vice President
Apr 13 '25
Option Exercise
0.00
1,641
0
29,698
Beers David C
Chief Financial Officer
Apr 13 '25
Option Exercise
0.00
1,025
0
18,561
Brigido Stephen
Pres., Functional Regeneration
Feb 17 '25
Option Exercise
0.00
10,000
0
11,641
Beers David C
Chief Financial Officer
Feb 17 '25
Option Exercise
0.00
12,500
0
21,932
Haines John R
Senior Exec Vice President
Feb 17 '25
Option Exercise
0.00
20,000
0
35,092
$20.27
price up icon 0.35%
$67.24
price down icon 2.81%
$31.69
price down icon 0.93%
$33.23
price down icon 0.81%
$114.98
price down icon 0.20%
biotechnology ONC
$253.97
price up icon 0.51%
Capitalizzazione:     |  Volume (24 ore):